IL6 and neoplasm: This dysregulation is particularly pronounced in HIV-HL patients presenting with bulky disease, who demonstrate significantly higher IL-2R (p=0.04) and IL-6 (p=0.03) compared to HIV-positive patients without bulky tumor burden (Table 3).